Pooled semaglutide trials show 16% lower kidney composite risk
This participant-level pooled analysis extends semaglutide kidney-protection data beyond dedicated chronic kidney disease (CKD) populations to patients with atherosclerotic cardiovascular disease, obesity, and type 2 diabetes, across subcutaneous and oral formulations.
📅 Journal publication: Oct 2026(online Aug 7, 2026)·Last updated: Nov 19, 2026
Semaglutide offers potential kidney benefits in cardio-metabolic diseases.
Understanding the renal impact of semaglutide can guide dosing and management in patients with cardio-kidney-metabolic diseases. Pooled data from 30,787 participants showed significant improvement in kidney outcomes with semaglutide treatment. Although encouraging, individual patient response may vary. The analysis informs potential semaglutide benefits but warrants clinical correlation. Semaglutide shows promise in improving kidney outcomes in cardio-kidney-metabolic diseases.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Mann JFE, Badve SV, Baeres FMM, Belmar N, Brown-Frandsen K, Buse JB, Colhoun HM, Deanfield JE, Engelmann MDM, Hovingh GK, Idorn T, Lincoff AM, Lingvay I, Mahaffey KW, McGuire DK, Pratley RE, Rasmussen S, Rossing P, Sattar N, Tuttle KR, Perkovic V
Citation:Mann JFE, Badve SV, Baeres FMM, et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. The lancet. Diabetes & endocrinology. 2026;14(10):818-830. doi:10.1016/S2213-8587(26)00134-8